Blue nevus-like lesions constitute a category of melanocytic lesions that are clinically identified by their blue coloration. Histologically, they exhibit two primary features: a dermal location and intense pigmentation. The latest World Health Organization classification categorizes blue melanocytic lesions into benign entities (dermal melanocytoses, blue nevus, and deep penetrating nevus), melanocytic tumors with low-to-intermediate malignant potential (pigmented epithelioid melanocytoma), and malignant lesions (blue nevus-like melanoma and melanoma arising in blue nevi). Clinically, blue nevi are enduring and stable lesions, displaying a structureless blue pigmentation clinically and dermatoscopically, with a straightforward histologic diagnosis. On the contrary, lesions with recent onset and/or rapid growth are more commonly associated with diagnoses falling within the intermediate part of the spectrum or with melanoma. These lesions often present with a blue color along with additional features such as black blotches, irregular vessels, and irregular pigmented globules. They typically emerge de novo without recognizable precursors, and they pose significant challenges for patient management. Melanoma on a blue nevus is an exceedingly rare entity with only a few cases described to date. Histologically, differentiating between lesions with intermediate malignant potential and melanoma is always challenging, necessitating a comprehensive evaluation of all morphologic findings of the lesion.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.clindermatol.2024.09.003 | DOI Listing |
Clin Dermatol
September 2024
Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples, Italy. Electronic address:
J Cutan Pathol
December 2024
Department of Diagnostic Pathology, Shizuoka Cancer Center Hospital, Sunto, Japan.
Ital J Dermatol Venerol
October 2022
Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
Background: Nevoid melanoma (NeM) is a rare variant of melanoma resembling melanocytic nevus. The aim of the study was to systematically review the dermoscopic features of NeM.
Methods: A hospital-based retrospective study was conducted.
Am J Dermatopathol
June 2022
Departments of Pathology, and.
Preferentially expressed antigen in melanoma (PRAME) is an immunohistochemical biomarker that is diffusely expressed in most cutaneous melanomas and is negative in most benign nevi. Histologically challenging dermal melanocytic neoplasms, such as cellular blue nevi (CBN) and deep penetrating nevi (DPN), and soft tissue tumors with melanocytic differentiation, such as clear cell sarcoma and perivascular epithelioid cell tumor, may resemble primary or metastatic melanoma. PRAME immunohistochemistry (IHC) was applied to archived formalin-fixed, paraffin-embedded specimens of various dermal melanocytic neoplasms and soft tissue neoplasms with melanocytic differentiation.
View Article and Find Full Text PDFAm J Surg Pathol
September 2021
Departments of Pathology.
Distinguishing cellular blue nevi (CBNs) and atypical CBNs from blue nevus-like melanoma (BNLM) can be diagnostically challenging. Immunohistochemistry may inform the diagnosis in a subset of cases but is not always diagnostic. Further, ancillary molecular testing is expensive and often requires significant tissue to complete.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!